MX2018009947A - Metodos y composiciones para restablecer la funcion de p53 mutante. - Google Patents
Metodos y composiciones para restablecer la funcion de p53 mutante.Info
- Publication number
- MX2018009947A MX2018009947A MX2018009947A MX2018009947A MX2018009947A MX 2018009947 A MX2018009947 A MX 2018009947A MX 2018009947 A MX2018009947 A MX 2018009947A MX 2018009947 A MX2018009947 A MX 2018009947A MX 2018009947 A MX2018009947 A MX 2018009947A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- mutant
- methods
- function
- progression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Abstract
Las mutaciones en oncogenes y supresores de tumor contribuyen al desarrollo y progreso de cáncer. La presente invención describe compuesto y métodos para restablecer la función natural del p53 mutante. Los compuestos de la presente invención pueden unirse al p53 mutante y restablecer la capacidad del p53 mutante para unirse al ADN y activar los efectores involucrados corriente abajo en la supresión de tumor. Pueden usarse los compuestos descritos para reducir el progreso de cánceres que contienen una mutación de p53.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662297450P | 2016-02-19 | 2016-02-19 | |
PCT/US2017/018511 WO2017143291A1 (en) | 2016-02-19 | 2017-02-17 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009947A true MX2018009947A (es) | 2019-01-21 |
Family
ID=59625486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009947A MX2018009947A (es) | 2016-02-19 | 2017-02-17 | Metodos y composiciones para restablecer la funcion de p53 mutante. |
Country Status (11)
Country | Link |
---|---|
US (4) | US10138219B2 (es) |
EP (1) | EP3416638A4 (es) |
JP (1) | JP6956098B2 (es) |
KR (1) | KR20180138200A (es) |
CN (1) | CN109069481A (es) |
AU (1) | AU2017221472B2 (es) |
BR (1) | BR112018016890A2 (es) |
CA (2) | CA3215564A1 (es) |
IL (2) | IL286839B (es) |
MX (1) | MX2018009947A (es) |
WO (1) | WO2017143291A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6956098B2 (ja) | 2016-02-19 | 2021-10-27 | ピーエムブイ ファーマシューティカルズ, インコーポレイテッド | 変異体p53機能を復元させるための方法および化合物 |
US11814373B2 (en) | 2019-09-23 | 2023-11-14 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
US11807644B2 (en) | 2020-05-12 | 2023-11-07 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
CN111686127B (zh) * | 2020-06-04 | 2022-02-15 | 华南理工大学 | 锌铁纳米材料在降解突变p53蛋白中的应用 |
CN113750246B (zh) * | 2020-06-04 | 2023-12-05 | 华南理工大学 | ZIF-8纳米材料在降解广谱突变p53蛋白中的应用 |
US20230024905A1 (en) * | 2020-06-22 | 2023-01-26 | Pmv Pharmaceuticals, Inc. | Uses of p53 x-ray co-crystal structures |
US20230049952A1 (en) * | 2020-06-24 | 2023-02-16 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
KR20230028371A (ko) * | 2020-06-24 | 2023-02-28 | 피엠브이 파마슈티컬스 인코포레이티드 | 돌연변이 p53 재활성화 화합물에 대한 동반 진단 도구 |
AU2021297716A1 (en) | 2020-06-24 | 2023-01-19 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
WO2022140520A1 (en) * | 2020-12-24 | 2022-06-30 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
WO2022213975A1 (en) * | 2021-04-08 | 2022-10-13 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
WO2023016434A1 (en) * | 2021-08-10 | 2023-02-16 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting mutant of p53 |
CN117916230A (zh) * | 2021-08-27 | 2024-04-19 | 杭州紫晶医药科技有限公司 | 作为p53调节剂的化合物 |
US11963953B2 (en) | 2022-01-27 | 2024-04-23 | Pmv Pharmaceuticals, Inc. | Deuterated compounds for restoring mutant p53 function |
WO2024017384A1 (zh) * | 2022-07-22 | 2024-01-25 | 深圳众格生物科技有限公司 | 恢复p53突变功能的化合物及其应用 |
WO2024041503A1 (en) * | 2022-08-22 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
WO2024083223A1 (zh) * | 2022-10-21 | 2024-04-25 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032175A2 (en) * | 1998-12-02 | 2000-06-08 | Pfizer Products Inc. | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
US6770652B2 (en) | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
WO2006014482A1 (en) | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
EP2268658B1 (en) | 2008-03-13 | 2015-12-09 | Universita'Degli Studi di Trieste | Peptides and aptamers thereof as specific modulators of mutant p53 function |
GB0808282D0 (en) * | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
EA020898B1 (ru) * | 2009-03-27 | 2015-02-27 | Мерк Шарп Энд Домэ Корп. | Ингибиторы репликации вируса гепатита c |
DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
RU2598842C2 (ru) | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
GB201110390D0 (en) * | 2011-06-20 | 2011-08-03 | Medical Res Council | Compounds for use in stabilising p53 mutants |
SG11201401043SA (en) * | 2011-09-09 | 2014-08-28 | Agency Science Tech & Res | P53 activating peptides |
WO2013101911A2 (en) | 2011-12-28 | 2013-07-04 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
US8822689B2 (en) | 2012-09-19 | 2014-09-02 | Merial Limited | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof |
JP6427599B2 (ja) | 2014-05-19 | 2018-11-21 | チャンスー ヘンルイ メディシン カンパニー,リミテッド | チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物 |
WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
CN104672241B (zh) * | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
JP6956098B2 (ja) | 2016-02-19 | 2021-10-27 | ピーエムブイ ファーマシューティカルズ, インコーポレイテッド | 変異体p53機能を復元させるための方法および化合物 |
-
2017
- 2017-02-17 JP JP2018544186A patent/JP6956098B2/ja active Active
- 2017-02-17 MX MX2018009947A patent/MX2018009947A/es unknown
- 2017-02-17 KR KR1020187026965A patent/KR20180138200A/ko active Search and Examination
- 2017-02-17 CA CA3215564A patent/CA3215564A1/en active Pending
- 2017-02-17 CN CN201780013450.6A patent/CN109069481A/zh active Pending
- 2017-02-17 WO PCT/US2017/018511 patent/WO2017143291A1/en active Application Filing
- 2017-02-17 BR BR112018016890-4A patent/BR112018016890A2/pt active IP Right Grant
- 2017-02-17 AU AU2017221472A patent/AU2017221472B2/en active Active
- 2017-02-17 CA CA3010847A patent/CA3010847A1/en active Pending
- 2017-02-17 EP EP17753995.4A patent/EP3416638A4/en active Pending
- 2017-02-17 IL IL286839A patent/IL286839B/en unknown
- 2017-02-17 US US15/436,333 patent/US10138219B2/en active Active
-
2018
- 2018-08-15 IL IL261175A patent/IL261175B/en unknown
- 2018-10-18 US US16/163,829 patent/US10640485B2/en active Active
-
2020
- 2020-03-16 US US16/819,934 patent/US11339141B2/en active Active
-
2022
- 2022-02-24 US US17/679,568 patent/US20220213062A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180138200A (ko) | 2018-12-28 |
IL286839A (en) | 2021-10-31 |
US20170240525A1 (en) | 2017-08-24 |
CA3010847A1 (en) | 2017-08-24 |
US20220213062A1 (en) | 2022-07-07 |
US10138219B2 (en) | 2018-11-27 |
IL261175A (en) | 2018-10-31 |
IL286839B (en) | 2022-08-01 |
AU2017221472B2 (en) | 2023-01-05 |
US10640485B2 (en) | 2020-05-05 |
CA3215564A1 (en) | 2017-08-24 |
BR112018016890A2 (pt) | 2019-02-12 |
IL261175B (en) | 2021-10-31 |
US20190119249A1 (en) | 2019-04-25 |
AU2017221472A1 (en) | 2018-07-26 |
US11339141B2 (en) | 2022-05-24 |
CN109069481A (zh) | 2018-12-21 |
EP3416638A1 (en) | 2018-12-26 |
EP3416638A4 (en) | 2019-07-17 |
JP6956098B2 (ja) | 2021-10-27 |
US20210002252A1 (en) | 2021-01-07 |
WO2017143291A1 (en) | 2017-08-24 |
JP2019512465A (ja) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018009947A (es) | Metodos y composiciones para restablecer la funcion de p53 mutante. | |
MX2022003456A (es) | Metodos y compuestos para restaurar la funcion del mutante p53. | |
MX2022015793A (es) | Terapia de combinacion para tratamiento de cancer. | |
MX2022015794A (es) | Herramienta complementaria de diagnostico para compuestos reactivantes p53 mutantes. | |
WO2021231474A9 (en) | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | |
MX2019004834A (es) | Anticuerpos de pd-1 y usos de estos. | |
EP3236969A4 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
EP3148580A4 (en) | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof | |
MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
EP3397766A4 (en) | COMPOSITIONS AND METHODS FOR SEARCHING FOR MUTATIONS IN THYROID CANCER | |
EP3143163A4 (en) | Gene mutations and copy number alterations of egfr, kras and met | |
EP3237149A4 (en) | Shaped abrasive particle fractions and method of forming same | |
AU2024202350A1 (en) | Methods and compositions related to NK cell and anti-PDL1 cancer therapies | |
EP3500267A4 (en) | NICOTINAMIDE RIBOSIDE AND PTEROSTILBENE COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
MX2019013634A (es) | Composiciones y metodos para tratar cancer con mutaciones de braf atipicas. | |
EP3548064A4 (en) | ANTI-HRS ANTIBODIES AND COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | |
SE1950314A1 (en) | An axle disconnect and differential lock combination | |
EP3155080A4 (en) | Nano-tribology compositions and related methods including hard particles | |
EP3870160A4 (en) | COMPOUNDS AND METHODS FOR MITIGATING TUMOR PROGRESSION AND METASTASIS | |
HK1254254A1 (zh) | 用於檢測骨髓增殖性疾病中calr突變的方法和組合物 | |
IL290962A (en) | Threshold activated tracking particles | |
EP3525831A4 (en) | NANOPARTICLES FUNCTIONALIZED WITH GENEDITING TOOLS AND RELATED METHODS | |
MX2022001249A (es) | Tratamiento de tumores evasivos inmunitarios. | |
EP3412287A4 (en) | APPLICATION OF PHOSPHODIESTERASE 4 INHIBITOR ZL-N-91 IN THE PREPARATION OF DRUGS FOR LUNG CANCER CELL PROLIFERATION AND METASTASES | |
MX2017006806A (es) | Extractos titulados de cynara scolymus para uso en el tratamiento del mesotelioma. |